Lidocaine clearance as pharmacokinetic parameter of metabolic hepatic activity in patients with impaired liver.

lidocaine liver failure pharmacokinetics

Journal

Journal of medical biochemistry
ISSN: 1452-8258
Titre abrégé: J Med Biochem
Pays: Serbia
ID NLM: 101315490

Informations de publication

Date de publication:
15 Mar 2023
Historique:
received: 15 06 2022
accepted: 10 10 2022
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: ppublish

Résumé

The study aimed to estimate lidocaine (LID) pharmacokinetic parameter values in patients with impaired liver function, level of correlation between the pharmacokinetic parameters and Child-Pugh class and change in pharmacokinetic parameters after liver tumor resection compared to the preoperative value. Patients with impaired liver function were subject to the LID test 1 day prior to, 3 and 7 days after the intervention. LID was administered in single i.v. dose of 1 mg/kg. Blood samples were collected at 15, 30 and 90 minutes after drug administration. Non-compartmental analysis was applied for calculating the pharmacokinetic parameters. The study included 17 patients with the diagnosis of cirrhosis and 41 patients with liver tumor. In both groups of patients, the values of the coefficients of correlation show the best correlation between clearance (CL) and Child-Pugh score (-0.693, p<0.005) over other pharmacokinetic parameters. The results indicate worsening hepatic function on 3rd day after operation in comparison to the values of LID CL prior to operation (mean LID CL for patients with Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively; while for B class are 16.89 L/h, 22.65 L/h, respectively). On day 7th, the values of LID CL (mean value for patients with Child-Pugh class A and B are 40.98 L/h and 21.46 L/h, respectively) are increased in comparison to 3rd day after. LID pharmacokinetic parameters consequently changed according to the severity of liver impairment, assessed by Child-Pugh score. Values of LID CL and volume of distribution (Vd) coupled with standard biochemical parameters may be used for preoperative assessment of liver function and monitoring of its postoperative recovery. Cilj studije bila je procena vrednosti farmakokinetičkih parametara lidokaina (LID) kod pacijenata sa oštećenom funkcijom jetre, stepena korelacije između farmakokinetičkih parametara i Child-Pugh klase i promene farmakokinetičkih parametara posle resekcije tumora jetre u odnosu na preoperativnu vrednost. Pacijenti sa oštećenom funkcijom jetre bili su podvrgnuti LID testu 1 dan pre, 3. i 7. dana nakon intervencije. LID je primenjen u pojedinačnoj i.v. dozi od 1 mg/kg. Uzorci krvi su sakupljeni 15, 30 i 90 minuta nakon primene leka. Za izračunavanje farmakokinetičkih parametara primenjena je neprostorna analiza. Studijom je obuhvaćeno 17 pacijenata sa dijagnozom ciroze i 41 pacijent sa tumorom jetre. Kod obe grupe pacijenata, vrednosti koeficijenata korelacije pokazuju najbolju korelaciju između klirensa LID (CL) i Child-Pugh skora (-0,693, p<0,005) u odnosu na ostale farmakokinetičke parametre. Rezultati ukazuju na pogoršanje funkcije jetre 3. dana nakon operacije u poređenju sa vrednostima LID CL pre operacije (srednje vrednosti LID CL kod pacijenata Child-Pugh grupe A iznosile su 25,91 L/h, 41,59 L/h, respektivno; dok su kod pacijenata u klasi B iznosile 16,89 L/h, 22,65 L/h, respektivno). Sedmog dana vrednosti LID CL (srednja vrednost u Child-Pugh grupi A i B iznosile su 40,98 L/h i 21,46 L/h, respektivno) bile su veće u odnosu na 3. dan posle hirurške intervencije. Farmakokinetički parametri LID se razlikuju u zavisnosti od težine oštećenja jetre, procenjenih Child-Pugh skorom. Vrednosti farmakokinetičkih parametara LID u kombinaciji sa standardnim biohemijskim parametrima mogu se koristiti za preoperativnu procenu funkcije jetre i praćenje njenog postoperativnog oporavka.

Sections du résumé

Background UNASSIGNED
The study aimed to estimate lidocaine (LID) pharmacokinetic parameter values in patients with impaired liver function, level of correlation between the pharmacokinetic parameters and Child-Pugh class and change in pharmacokinetic parameters after liver tumor resection compared to the preoperative value.
Methods UNASSIGNED
Patients with impaired liver function were subject to the LID test 1 day prior to, 3 and 7 days after the intervention. LID was administered in single i.v. dose of 1 mg/kg. Blood samples were collected at 15, 30 and 90 minutes after drug administration. Non-compartmental analysis was applied for calculating the pharmacokinetic parameters.
Results UNASSIGNED
The study included 17 patients with the diagnosis of cirrhosis and 41 patients with liver tumor. In both groups of patients, the values of the coefficients of correlation show the best correlation between clearance (CL) and Child-Pugh score (-0.693, p<0.005) over other pharmacokinetic parameters. The results indicate worsening hepatic function on 3rd day after operation in comparison to the values of LID CL prior to operation (mean LID CL for patients with Child-Pugh class A are 25.91 L/h, 41.59 L/h, respectively; while for B class are 16.89 L/h, 22.65 L/h, respectively). On day 7th, the values of LID CL (mean value for patients with Child-Pugh class A and B are 40.98 L/h and 21.46 L/h, respectively) are increased in comparison to 3rd day after.
Conclusions UNASSIGNED
LID pharmacokinetic parameters consequently changed according to the severity of liver impairment, assessed by Child-Pugh score. Values of LID CL and volume of distribution (Vd) coupled with standard biochemical parameters may be used for preoperative assessment of liver function and monitoring of its postoperative recovery.
Uvod UNASSIGNED
Cilj studije bila je procena vrednosti farmakokinetičkih parametara lidokaina (LID) kod pacijenata sa oštećenom funkcijom jetre, stepena korelacije između farmakokinetičkih parametara i Child-Pugh klase i promene farmakokinetičkih parametara posle resekcije tumora jetre u odnosu na preoperativnu vrednost.
Metode UNASSIGNED
Pacijenti sa oštećenom funkcijom jetre bili su podvrgnuti LID testu 1 dan pre, 3. i 7. dana nakon intervencije. LID je primenjen u pojedinačnoj i.v. dozi od 1 mg/kg. Uzorci krvi su sakupljeni 15, 30 i 90 minuta nakon primene leka. Za izračunavanje farmakokinetičkih parametara primenjena je neprostorna analiza.
Rezultati UNASSIGNED
Studijom je obuhvaćeno 17 pacijenata sa dijagnozom ciroze i 41 pacijent sa tumorom jetre. Kod obe grupe pacijenata, vrednosti koeficijenata korelacije pokazuju najbolju korelaciju između klirensa LID (CL) i Child-Pugh skora (-0,693, p<0,005) u odnosu na ostale farmakokinetičke parametre. Rezultati ukazuju na pogoršanje funkcije jetre 3. dana nakon operacije u poređenju sa vrednostima LID CL pre operacije (srednje vrednosti LID CL kod pacijenata Child-Pugh grupe A iznosile su 25,91 L/h, 41,59 L/h, respektivno; dok su kod pacijenata u klasi B iznosile 16,89 L/h, 22,65 L/h, respektivno). Sedmog dana vrednosti LID CL (srednja vrednost u Child-Pugh grupi A i B iznosile su 40,98 L/h i 21,46 L/h, respektivno) bile su veće u odnosu na 3. dan posle hirurške intervencije.
Zaključak UNASSIGNED
Farmakokinetički parametri LID se razlikuju u zavisnosti od težine oštećenja jetre, procenjenih Child-Pugh skorom. Vrednosti farmakokinetičkih parametara LID u kombinaciji sa standardnim biohemijskim parametrima mogu se koristiti za preoperativnu procenu funkcije jetre i praćenje njenog postoperativnog oporavka.

Autres résumés

Type: Publisher (srp)
Cilj studije bila je procena vrednosti farmakokinetičkih parametara lidokaina (LID) kod pacijenata sa oštećenom funkcijom jetre, stepena korelacije između farmakokinetičkih parametara i Child-Pugh klase i promene farmakokinetičkih parametara posle resekcije tumora jetre u odnosu na preoperativnu vrednost.

Identifiants

pubmed: 36987422
doi: 10.5937/jomb0-38952
pii: jomb-42-2-2302304J
pmc: PMC10040201
doi:

Types de publication

Journal Article

Langues

eng

Pagination

304-310

Informations de copyright

2023 Marija Jovanović, Milena Kovačević, Sandra Vezmar-Kovačević, Ivan Palibrk, Jasna Bjelanović, Branislava Miljković, Katarina Vučićević, published by CEON/CEES.

Déclaration de conflit d'intérêts

All the authors declare that they have no conflict of interest in this work.Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.

Références

Surgery. 2000 Apr;127(4):464-71
pubmed: 10776439
Hepatol Int. 2011 Dec;5(4):941-8
pubmed: 21484114
Front Physiol. 2021 Nov 18;12:733868
pubmed: 34867441
Dig Liver Dis. 2009 Nov;41(11):798-806
pubmed: 19303376
Ann Surg. 2013 Jan;257(1):27-36
pubmed: 22836216
Ther Drug Monit. 2001 Apr;23(2):81-92
pubmed: 11294522
HPB (Oxford). 2014 May;16(5):407-21
pubmed: 23991862
Eur J Drug Metab Pharmacokinet. 2002 Oct-Dec;27(4):243-7
pubmed: 12587953
J Hepatol. 2018 Sep;69(3):718-735
pubmed: 29777749
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666
pubmed: 31401364
Acta Pol Pharm. 2002 Jul-Aug;59(4):321-4
pubmed: 12403308
Updates Surg. 2020 Dec;72(4):925-938
pubmed: 32749596
Curr Opin Crit Care. 2007 Apr;13(2):207-14
pubmed: 17327744
World J Gastroenterol. 2016 Jan 21;22(3):1260-78
pubmed: 26811663
ESMO Open. 2016 Mar 17;1(2):e000042
pubmed: 27843598
Aliment Pharmacol Ther. 1999 Jan;13(1):67-75
pubmed: 9892881
Liver Int. 2008 Jul;28(6):767-80
pubmed: 18647141
Ann Med Surg (Lond). 2018 Aug 23;34:4-10
pubmed: 30181871
Hepatogastroenterology. 2008 Mar-Apr;55(82-83):539-43
pubmed: 18613404
Clin Pharmacol Ther. 2004 Jan;75(1):80-8
pubmed: 14749694
Liver Transpl. 2006 Apr;12(4):544-9
pubmed: 16482561
Curr Opin Gastroenterol. 2015 May;31(3):199-208
pubmed: 25714706
Dig Dis Sci. 1999 Apr;44(4):789-95
pubmed: 10219840
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Sep 1;1207:123362
pubmed: 35839626
Semin Liver Dis. 2013 Aug;33(3):204-12
pubmed: 23943101
Ther Drug Monit. 1996 Aug;18(4):372-7
pubmed: 8857553
Indian J Gastroenterol. 2007 Jul-Aug;26(4):167-9
pubmed: 17986743
J Med Biochem. 2022 Apr 8;41(2):176-183
pubmed: 35510200
Ther Clin Risk Manag. 2020 Apr 05;16:223-232
pubmed: 32308400
Clin Transplant. 2004 Jun;18(3):235-41
pubmed: 15142042

Auteurs

Marija Jovanović (M)

University of Belgrade, Faculty of Pharmacy, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade.

Milena Kovačević (M)

University of Belgrade, Faculty of Pharmacy, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade.

Sandra Vezmar-Kovačević (S)

University of Belgrade, Faculty of Pharmacy, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade.

Ivan Palibrk (I)

University Clinical Centre of Serbia, Department for Anesthesia and Reanimation, Section at Clinic for Digestive Surgery, Belgrade.

Jasna Bjelanović (J)

University Clinical Centre of Serbia, Center for Medical Biochemistry, Belgrade.

Branislava Miljković (B)

University of Belgrade, Faculty of Pharmacy, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade.

Katarina Vučićević (K)

University of Belgrade, Faculty of Pharmacy, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade.

Classifications MeSH